Marco Investment Management LLC Reduces Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Marco Investment Management LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,158 shares of the medical research company’s stock after selling 197 shares during the quarter. Marco Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $6,453,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. WCM Investment Management LLC lifted its position in Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock worth $527,524,000 after acquiring an additional 2,928 shares during the period. Phoenix Holdings Ltd. lifted its position in Thermo Fisher Scientific by 21.4% during the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after acquiring an additional 1,654 shares during the period. DMC Group LLC lifted its position in Thermo Fisher Scientific by 16.5% during the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock worth $300,000 after acquiring an additional 84 shares during the period. S. R. Schill & Associates lifted its holdings in shares of Thermo Fisher Scientific by 106.3% in the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after buying an additional 792 shares during the period. Finally, Check Capital Management Inc. CA acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $219,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded up $1.87 during trading hours on Friday, reaching $573.60. The company had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.39 and a current ratio of 1.70. The stock has a fifty day moving average of $573.60 and a 200-day moving average of $530.40. The company has a market capitalization of $218.95 billion, a price-to-earnings ratio of 36.79, a PEG ratio of 2.42 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.56 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,277 shares of company stock worth $28,513,384. Insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on TMO shares. Barclays boosted their price objective on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a report on Thursday. Evercore ISI boosted their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. The Goldman Sachs Group boosted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Royal Bank of Canada upped their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, Robert W. Baird reduced their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $606.76.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.